查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1943705

专业药局市场－全球产业规模、份额、趋势、竞争格局、机会及预测：按所有权、治疗领域、地区和竞争格局划分，2021-2031年

Specialty Pharmacy Market - Global Industry Size, Share, Trends, Competition, Opportunity and Forecast, Segmented By Ownership, By Therapy Area, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球特药市场预计将从 2025 年的 1,284.1 亿美元成长到 2031 年的 1,928.2 亿美元，复合年增长率达到 7.01%。

该细分市场专注于高成本、高管理要求的药物疗法的管理和分销，这些疗法专为患有罕见疾病、慢性病或复杂疾病的患者设计，需要特定的剂量和治疗方案。市场成长的主要驱动因素是全球人口老化、慢性病盛行率上升以及强大的药物研发管线，尤其专注于孤儿药和生物製药。这些基本因素使得专科药局模式中固有的专业供应链能力和临床管控成为确保病人安全和治疗依从性的关键。

市场概览
预测期 2027-2031
市场规模：2025年 1284.1亿美元
市场规模：2031年 1928.2亿美元
复合年增长率：2026-2031年 7.01%
成长最快的细分市场 医院
最大的市场 北美洲

儘管市场成长势头强劲，但由于治疗费用高昂且严格的报销通讯协定，患者难以获得治疗，因此该市场面临许多挑战。这些治疗带来的巨大经济负担对医疗系统和支付者造成了沉重压力，也凸显了製定强有力的成本控制策略的必要性。美国管理式医疗药房学会（Academy of Managed Care Pharmacy）的报告显示，到2024年，专科药物将占药品总支出的51%，这表明这些重要疗法具有巨大的经济影响和管理复杂性。

市场驱动因素

基因疗法和生物製药的快速创新是全球专科药房市场发展的关键驱动力，从根本上改变了罕见疾病和复杂疾病的治疗模式。这一发展势头体现在大量高价值疗法的研发管线中，这些疗法需要专科药房运作的核心——独特的临床专业知识、病患支援服务和低温运输物流。孤儿药的研发投入显着增加，确保特定患者群体能够获得以往难以获得或难以企及的标靶治疗。根据美国食品药物管理局（FDA）于2025年1月发布的《2024年新药认证报告》，罕见疾病治疗药物将占2024年核准的前50种新药的50%以上。这一增长凸显了专科药房在安全提供这些改变生命的治疗方法方面发挥的关键作用。

同时，随着专利到期，生物相似药的激增正在重塑市场动态，为成熟的生物製药品牌提供更具成本效益的替代方案。随着重磅生物製药失去专利保护，医疗系统和支付方正积极推广生物相似药的使用，以减轻专科治疗日益沉重的经济负担，同时维持高标准的医疗服务。这种转变不仅降低了单位成本，也透过减少经济障碍，扩大了患者获得重要治疗方法的机会。 2025年9月，美国可及药品协会（Association for Accessible Medicines）报告称，生物相似药预计在2024年为美国医疗系统节省202亿美元。儘管如此，对复杂药物的整体需求仍在推动市场扩张。美国卫生系统药师协会（American Society of Health-System Pharmacists）在2025年指出，2024年美国药品总支出将成长10.2%，达到8,059亿美元。

市场挑战

治疗成本不断上涨，加上严格的报销通讯协定，为全球专科药局市场的成长带来了巨大障碍。为了控製成本，保险公司和支付方经常采取严格的用药管理策略，例如强制执行阶梯通讯协定和复杂的预先核准要求。这些措施增加了行政负担，延误了治疗的启动，限制了患者的就医途径，并可能导致患者用药依从性降低。因此，专科药局的处方笺量和商机都会减少。

这种财务压力迫使医疗系统限製药品目录的采用，并积极进行价格谈判，阻碍了市场流动性。根据美国卫生系统药剂师协会（ASHP）的数据，到2024年，医生诊室的药品支出将年增14.6%，其中高成本专科药物是主要成长动力。沉重的财务负担迫使支付方收紧预算控制，造成一种限制性环境，使得医疗基础设施难以消化快速推出的昂贵新疗法，从而抑制了市场扩张。

市场趋势

药品福利管理机构 (PBM)、支付方和专科药局之间日益加剧的垂直整合，正在从根本上重塑病患用药管道和市场力量结构。大型健康保险公司正积极进行整合，以获取高成本专科药物的全部经济价值，并透过其附属的配药管道有效地引导处方笺量。这种结构性转变使垂直整合的公司对药品目录拥有更大的控制权，并使其能够维持更高的利润率，从而为争夺有限的药品供应而竞争的独立药房和医院附属药房设置了巨大的障碍。根据《贝克尔医院评论》2025年6月刊的预测，到2024年，由垂直整合的PBM机构拥有的前三大专科药房将占据专科处方药收入的三分之二。

同时，人工智慧的快速应用正在革新专科药局领域的用药依从通讯协定和工作流程优化。相关人员正在部署先进的演算法来自动化复杂的行政任务，例如福利核实和事前核准，这些任务通常会延误治疗的启动。这些人工智慧驱动的系统不仅消除了营运瓶颈，还能进行预测分析，识别用药依从性有风险的患者，从而促进主动的临床干预。为了反映这一趋势，《管理式医疗与专科药房杂誌》在2025年1月的报告中指出，92%的受访医疗管理机构预测，未来五年内，人工智慧将应用于超过一半的事前核准审核中。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球特药市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 依所有权类型（独立、医院附属、其他）
    • 依治疗领域（癌症、类风湿性关节炎、血友病、C型肝炎、多发性硬化症、其他）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美特药市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国家分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲特药市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国家分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区特药市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲专科药局市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东和非洲：国家分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲特药市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国家分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 司机
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 最新进展

第十三章 全球特药市场：SWOT分析

第十四章 波特五力分析

  • 产业竞争
  • 新进入者的可能性
  • 供应商电力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • CVS Health Corporation
  • Walgreens Boots Alliance, Inc.
  • Express Scripts Holding Company
  • UnitedHealth Group Incorporated
  • Humana Inc.
  • BioScrip, Inc.
  • Diplomat Pharmacy, Inc.
  • Accredo Health Group, Inc.
  • Curant Health
  • Avella Specialty Pharmacy

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 8024

The Global Specialty Pharmacy Market is projected to expand from USD 128.41 Billion in 2025 to USD 192.82 Billion by 2031, achieving a compound annual growth rate of 7.01%. This sector focuses on the management and distribution of high-cost, high-touch medication therapies tailored for patients with rare, chronic, or complex conditions that demand specific administration and handling. The market's growth is chiefly propelled by an aging global population, the increasing prevalence of chronic diseases, and a robust pharmaceutical pipeline emphasizing orphan drugs and biologics. These foundational factors necessitate the specialized supply chain capabilities and clinical management inherent in specialty pharmacy models to guarantee patient safety and treatment adherence.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 128.41 Billion
Market Size 2031USD 192.82 Billion
CAGR 2026-20317.01%
Fastest Growing SegmentHospital-based
Largest MarketNorth America

Despite this positive growth trajectory, the market faces significant hurdles due to the high cost of therapies and strict reimbursement protocols that can impede patient access. The substantial financial weight of these treatments places immense pressure on health systems and payers, amplifying the need for robust cost-containment strategies. Illustrating the economic impact and management complexities associated with these essential treatments, the Academy of Managed Care Pharmacy reported that specialty medicines comprised 51% of total pharmacy spending in 2024.

Market Driver

Rapid innovation in gene therapies and biologics serves as a primary engine for the Global Specialty Pharmacy Market, fundamentally transforming the treatment landscape for rare and complex diseases. This momentum is defined by a strong pipeline of high-value treatments that require the distinct clinical expertise, patient support services, and cold-chain logistics central to specialty pharmacy operations. The focus on orphan drugs has intensified significantly, ensuring that niche patient populations gain access to targeted therapies that were previously restricted or unavailable. According to the FDA's '2024 New Drug Therapy Approvals' report released in January 2025, the agency approved 50 novel drugs in 2024, with therapies for rare diseases constituting over 50% of these approvals, a surge that reinforces the critical role of specialty pharmacies in safely delivering these life-changing regimens.

Concurrently, the proliferation of biosimilars following patent expirations is reshaping market dynamics by providing cost-effective alternatives to established biologic brands. As major blockbuster biologics lose exclusivity, health systems and payers are aggressively encouraging biosimilar adoption to alleviate the rising financial burden of specialty care while upholding high treatment standards. This shift not only lowers per-unit costs but also broadens patient access to critical therapies by reducing economic barriers; the Association for Accessible Medicines reported in September 2025 that biosimilars yielded $20.2 billion in savings for the U.S. healthcare system in 2024. Despite these savings, the aggregate demand for complex medications continues to fuel market expansion, with the American Society of Health-System Pharmacists noting in 2025 that overall U.S. pharmaceutical expenditures rose by 10.2% in 2024 to reach $805.9 billion.

Market Challenge

The elevated cost of therapy combined with rigorous reimbursement protocols creates a substantial barrier to the growth of the Global Specialty Pharmacy Market. Insurance providers and payers frequently deploy strict utilization management strategies to curb these rising expenses, often mandating step therapy protocols and complex prior authorization requirements. These measures generate administrative burdens and delay the initiation of treatment, which restricts patient access and can lead to lower medication adherence rates, ultimately reducing the volume of dispensed prescriptions and revenue opportunities for specialty pharmacies.

This financial strain compels health systems to limit formulary inclusions and negotiate aggressive pricing structures, thereby hampering market fluidity. Data from the American Society of Health-System Pharmacists indicates that drug expenditures for clinics rose by 14.6 percent in 2024 compared to the previous year, an increase driven primarily by high-cost specialty agents. This heavy economic burden necessitates tighter budget controls from payers, establishing a restrictive environment where market expansion is moderated by the healthcare infrastructure's inability to financially absorb the rapid introduction of expensive new therapies.

Market Trends

The increasing vertical integration of pharmacy benefit managers (PBMs), payers, and specialty pharmacies is fundamentally restructuring patient access mechanisms and market control. Major health insurers are actively consolidating operations to capture the full economic value of high-cost specialty therapies, effectively directing prescription volumes toward their own affiliated dispensing channels. This structural shift enables vertically integrated entities to tighten formulary management and retain higher margins, creating significant obstacles for independent and hospital-owned pharmacies striving to compete for limited distribution drugs. According to a June 2025 article in Becker's Hospital Review, the three largest specialty pharmacies-all owned by vertically integrated PBM organizations-accounted for two-thirds of specialty prescription revenue in 2024.

Simultaneously, the rapid adoption of artificial intelligence is revolutionizing medication adherence protocols and workflow optimization within the specialty pharmacy sector. Stakeholders are implementing advanced algorithms to automate complex administrative tasks such as benefits verification and prior authorization, which traditionally cause delays in therapy initiation. These AI-driven systems not only reduce operational bottlenecks but also facilitate predictive analytics to identify patients at risk of non-adherence, allowing for proactive clinical interventions. Reflecting this trend, the Journal of Managed Care & Specialty Pharmacy reported in January 2025 that 92% of managed care respondents anticipate AI will be incorporated into more than half of all prior authorization reviews within the next five years.

Key Market Players

  • CVS Health Corporation
  • Walgreens Boots Alliance, Inc.
  • Express Scripts Holding Company
  • UnitedHealth Group Incorporated
  • Humana Inc.
  • BioScrip, Inc.
  • Diplomat Pharmacy, Inc.
  • Accredo Health Group, Inc.
  • Curant Health
  • Avella Specialty Pharmacy

Report Scope

In this report, the Global Specialty Pharmacy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Specialty Pharmacy Market, By Ownership

  • Standalone
  • Hospital-Based
  • Others

Specialty Pharmacy Market, By Therapy Area

  • Cancer
  • Rheumatoid Arthritis
  • Hemophilia
  • Hepatitis C
  • Multiple Sclerosis
  • Others

Specialty Pharmacy Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Specialty Pharmacy Market.

Available Customizations:

Global Specialty Pharmacy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Specialty Pharmacy Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Ownership (Standalone, Hospital-Based, Others)
    • 5.2.2. By Therapy Area (Cancer, Rheumatoid Arthritis, Hemophilia, Hepatitis C, Multiple Sclerosis, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Specialty Pharmacy Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Ownership
    • 6.2.2. By Therapy Area
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Specialty Pharmacy Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Ownership
        • 6.3.1.2.2. By Therapy Area
    • 6.3.2. Canada Specialty Pharmacy Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Ownership
        • 6.3.2.2.2. By Therapy Area
    • 6.3.3. Mexico Specialty Pharmacy Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Ownership
        • 6.3.3.2.2. By Therapy Area

7. Europe Specialty Pharmacy Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Ownership
    • 7.2.2. By Therapy Area
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Specialty Pharmacy Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Ownership
        • 7.3.1.2.2. By Therapy Area
    • 7.3.2. France Specialty Pharmacy Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Ownership
        • 7.3.2.2.2. By Therapy Area
    • 7.3.3. United Kingdom Specialty Pharmacy Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Ownership
        • 7.3.3.2.2. By Therapy Area
    • 7.3.4. Italy Specialty Pharmacy Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Ownership
        • 7.3.4.2.2. By Therapy Area
    • 7.3.5. Spain Specialty Pharmacy Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Ownership
        • 7.3.5.2.2. By Therapy Area

8. Asia Pacific Specialty Pharmacy Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Ownership
    • 8.2.2. By Therapy Area
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Specialty Pharmacy Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Ownership
        • 8.3.1.2.2. By Therapy Area
    • 8.3.2. India Specialty Pharmacy Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Ownership
        • 8.3.2.2.2. By Therapy Area
    • 8.3.3. Japan Specialty Pharmacy Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Ownership
        • 8.3.3.2.2. By Therapy Area
    • 8.3.4. South Korea Specialty Pharmacy Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Ownership
        • 8.3.4.2.2. By Therapy Area
    • 8.3.5. Australia Specialty Pharmacy Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Ownership
        • 8.3.5.2.2. By Therapy Area

9. Middle East & Africa Specialty Pharmacy Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Ownership
    • 9.2.2. By Therapy Area
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Specialty Pharmacy Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Ownership
        • 9.3.1.2.2. By Therapy Area
    • 9.3.2. UAE Specialty Pharmacy Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Ownership
        • 9.3.2.2.2. By Therapy Area
    • 9.3.3. South Africa Specialty Pharmacy Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Ownership
        • 9.3.3.2.2. By Therapy Area

10. South America Specialty Pharmacy Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Ownership
    • 10.2.2. By Therapy Area
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Specialty Pharmacy Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Ownership
        • 10.3.1.2.2. By Therapy Area
    • 10.3.2. Colombia Specialty Pharmacy Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Ownership
        • 10.3.2.2.2. By Therapy Area
    • 10.3.3. Argentina Specialty Pharmacy Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Ownership
        • 10.3.3.2.2. By Therapy Area

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Specialty Pharmacy Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. CVS Health Corporation
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Walgreens Boots Alliance, Inc.
  • 15.3. Express Scripts Holding Company
  • 15.4. UnitedHealth Group Incorporated
  • 15.5. Humana Inc.
  • 15.6. BioScrip, Inc.
  • 15.7. Diplomat Pharmacy, Inc.
  • 15.8. Accredo Health Group, Inc.
  • 15.9. Curant Health
  • 15.10. Avella Specialty Pharmacy

16. Strategic Recommendations

17. About Us & Disclaimer